Background/Aims: Memantine has been approved by the Food and Drug Administration for the treatment of moderate-to-severe Alzheimer's disease (AD). However, the effect of memantine on patients with mild-to-moderate AD is unclear. Methods: This study is a post hoc analysis of a double-blind clinical trial. Donepezil was used as the standard control treatment. Outcomes included score changes from baseline to week 24 on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a modified 20-item Activities of Daily Living Scale (ADL), the Neuropsychiatric Inventory (NPI), and the Mini-Mental State Examination (MMSE) as well as the score of the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-Plus). Results: One hundred sixty-seven AD patients with an MMSE score of 10-24 were analyzed. No significant differences in the score changes from baseline to week 24 on all outcomes or the four subscales of the ADAS-cog were observed between the two treatment groups. Donepezil resulted in an improved score for naming ability on the ADAS-cog compared to memantine (p = 0.036), whereas memantine more effectively reduced agitation as measured by the NPI compared to donepezil (p = 0.039). Conclusion: These findings support the efficacy of memantine for the treatment of mild-to-moderate AD, especially in patients with agitation.

Keywords:
Alzheimerߣs disease, mild to moderate, Memantine, Donepezil
1.
Zhang N, Du HJ, Wang JH, Cheng Y: A pilot study on the relationship between thyroid status and neuropsychiatric symptoms in patients with Alzheimer disease. Chin Med J (Engl) 2012;125:3211-3216.
2.
van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; Memantine MEM-MD-01 Study Group: A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:136-143.
3.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
4.
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54.
5.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324.
6.
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S: Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-715.
7.
Bakchine S, Loft H: Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008;13:97-107.
8.
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-89.
9.
Cheng Y, Zhang N, Du HJ, Chen HB, Peng DT, Cai XJ, Xiao SF, Li X, Ma C, Feng YQ, Mo X, Gao ZL, Zhao G, Zhang GK: Multicenter controlled randomized clinical trial of akatinol memantine for treatment of Alzheimer's disease (in Chinese). Chin J Neurol 2009;42:268-272.
10.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
11.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
13.
Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995;45:1451-1455.
14.
Cumbo E, Ligori LD: Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. J Alzheimers Dis 2014;39:477-485.
15.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
16.
Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
17.
Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T: Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):8-18.
18.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
19.
Pomara N, Ott BR, Peskind E, Resnick EM: Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 2007;21:60-64.
20.
Schneider LS, Insel PS, Weiner MW: Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 2011;68:58-66.
21.
Schneider LS, Sano M: Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009;5:388-397.
22.
Holthoff V, Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Sternberg K, Tennigkeit F: Memantine effects measured with the relevant outcome scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study. Int J Geriatr Psychiatry 2013;28:164-172.
23.
McClendon MJ, Hernandez S, Smyth KA, Lerner AJ: Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J Alzheimers Dis 2009;16:577-583.
24.
Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD: Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014;311:33-44.
25.
Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M: Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010;17:405-412.
26.
Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, Dziewczapolski G, Nakamura T, Cao G, Pratt AE, Kang YJ, Tu S, Molokanova E, McKercher SR, Hires SA, Sason H, Stouffer DG, Buczynski MW, Solomon JP, Michael S, Powers ET, Kelly JW, Roberts A, Tong G, Fang-Newmeyer T, Parker J, Holland EA, Zhang D, Nakanishi N, Chen HS, Wolosker H, Wang Y, Parsons LH, Ambasudhan R, Masliah E, Heinemann SF, Pina-Crespo JC, Lipton SA: Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 2013;110:E2518-E2527.
27.
Davis ML, Barrett AM: Selective benefit of donepezil on oral naming in Alzheimer's disease in men compared to women. CNS Spectr 2009;14:175-176.
28.
Weiner MW, Sadowsky C, Saxton J, Hofbauer RK, Graham SM, Yu SY, Li S, Hsu HA, Suhy J, Fridman M, Perhach JL: Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. Alzheimers Dement 2011;7:425-435.
29.
Tanaka Y, Miyazaki M, Albert ML: Effects of increased cholinergic activity on naming in aphasia. Lancet 1997;350:116-117.
30.
Herrmann N, Cappell J, Eryavec GM, Lanctot KL: Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs 2011;25:425-433.
31.
Grossberg GT, Pejovic V, Miller ML, Graham SM: Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2009;27:164-172.
32.
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007;357:1382-1392.
33.
Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL: Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001;49:355-361.
34.
Song MS, Rauw G, Baker GB, Kar S: Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 2008;28:1989-2002.
35.
Kamat PK, Rai S, Swarnkar S, Shukla R, Ali S, Najmi AK, Nath C: Okadaic acid-induced tau phosphorylation in rat brain: role of NMDA receptor. Neuroscience 2013;238:97-113.
36.
Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L: Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:247-252.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.